Free Trial
NASDAQ:SCPH

scPharmaceuticals (SCPH) Stock Price, News & Analysis

scPharmaceuticals logo
$2.32 +0.02 (+0.87%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$2.32 0.00 (0.00%)
As of 04/4/2025 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About scPharmaceuticals Stock (NASDAQ:SCPH)

Key Stats

Today's Range
$2.21
$2.37
50-Day Range
$2.30
$3.68
52-Week Range
$2.20
$5.65
Volume
570,812 shs
Average Volume
341,958 shs
Market Capitalization
$116.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00
Consensus Rating
Buy

Company Overview

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Remove Ads

scPharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

SCPH MarketRank™: 

scPharmaceuticals scored higher than 66% of companies evaluated by MarketBeat, and ranked 295th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    scPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    scPharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about scPharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for scPharmaceuticals are expected to grow in the coming year, from ($1.53) to ($1.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of scPharmaceuticals is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of scPharmaceuticals is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    scPharmaceuticals has a P/B Ratio of 2.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about scPharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    11.99% of the float of scPharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    scPharmaceuticals has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in scPharmaceuticals has recently decreased by 9.71%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    scPharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    scPharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.99% of the float of scPharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    scPharmaceuticals has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in scPharmaceuticals has recently decreased by 9.71%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 3 people have searched for SCPH on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added scPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, scPharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.52% of the stock of scPharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    89.52% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about scPharmaceuticals' insider trading history.
Receive SCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SCPH Stock News Headlines

Craig-Hallum Sticks to Its Buy Rating for scPharmaceuticals (SCPH)
Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
scPharmaceuticals price target lowered to $12 from $20 at Maxim
Q4 2024 scPharmaceuticals Inc Earnings Call
scPharmaceuticals reports Q 4EPS (35c), consensus (39c)
See More Headlines

SCPH Stock Analysis - Frequently Asked Questions

scPharmaceuticals' stock was trading at $3.54 on January 1st, 2025. Since then, SCPH shares have decreased by 34.5% and is now trading at $2.32.
View the best growth stocks for 2025 here
.

scPharmaceuticals Inc. (NASDAQ:SCPH) announced its quarterly earnings data on Wednesday, March, 19th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.05. The firm had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.08 million. scPharmaceuticals had a negative net margin of 264.60% and a negative trailing twelve-month return on equity of 244.93%.

scPharmaceuticals (SCPH) raised $96 million in an initial public offering (IPO) on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that scPharmaceuticals investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
3/19/2025
Today
4/05/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SCPH
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$18.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+503.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-54,810,000.00
Net Margins
-264.60%
Pretax Margin
-264.60%

Debt

Sales & Book Value

Annual Sales
$36.33 million
Price / Cash Flow
N/A
Book Value
$1.04 per share
Price / Book
2.23

Miscellaneous

Free Float
47,278,000
Market Cap
$116.66 million
Optionable
Optionable
Beta
0.38
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (NASDAQ:SCPH) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners